



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Didier Hoarau et al.

Application No.: 10/518,173

Filing Date: December 10, 2004

Title: STEALTH LIPID NANOCAPSULES,  
METHODS FOR THE PREPARATION  
THEREOF AND USE THEREOF AS A  
CARRIER FOR ACTIVE  
PRINCIPLE(S)

) Group Art Unit: 1615

) Examiner: THURMAN K PAGE

) Confirmation No.: 5720

**SECOND  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a Second Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL AND ROONEY PC

Date January 5, 2007

By: Mary Katherine Baumeister  
Mary Katherine Baumeister  
Registration No. 26254

P.O. Box 1404  
Alexandria, VA 22313-1404  
1737 King Street, Suite 500  
Alexandria, VA 22314-2727  
703 836 6620

**Buchanan Ingersoll & Rooney PC**  
Attorneys & Government Relations Professionals



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of )  
Didier Hoarau et al. ) Group Art Unit: 1615  
Application No.: 10/518,173 ) Examiner: THURMAN K PAGE  
Filed: December 10, 2004 ) Confirmation No.: 5720  
For: STEALTH LIPID NANOCAPSULES, )  
METHODS FOR THE PREPARATION )  
THEREOF AND USE THEREOF AS A )  
CARRIER FOR ACTIVE PRINCIPLE(S) )

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request the Examiner's consideration of the documents listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

This Statement, Form PTO-1449 and the listed documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that an Examiner-initialed copy of the accompanying Form PTO-1449 be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: January 5, 2007

By: Mary Katherine Baumeister  
Mary Katherine Baumeister  
Registration No. 26254

P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620

(use as many sheets as necessary)

Sheet 1 of 2

JAN 05 2007

Application Number	10/518,173
Filing Date	December 10, 2004
First Named Inventor	Didier Hoarau et al.
Examiner Name	THURMAN K PAGE
Attorney Docket No.	1017753-000201

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Steerenberg et al., "Liposomes as a drug carrier system for <i>cis</i> -diamminedichloroplatinum (II). I. Binding capacity, stability and tumor cell growth inhibition in vitro", International Journal of Pharmaceutics, Vol. 40, pp. 51-62, 1987, Elsevier Science Publishers B.V., The Netherlands
	Newman et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", Cancer Chemother Pharmacol, Vol. 43, pp. 1-7, 1999, Springer-Verlag, Berlin
	Gasco et al., "Doxorubicine Englobed in Polybutylcyanoacrylate Nanocapsules: Behaviour in vitro and in vivo", Pharm. Acta Helv., Vol. 66, No. 2, pp. 47-49, 1991, Germany

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**SECOND  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/518,173
Filing Date	December 10, 2004
First Named Inventor	Didier Hoarau et al.
Examiner Name	THURMAN K PAGE
Attorney Docket No.	1017753-000201

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Klibanov et al., "Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target", Biochimica et Biophysica Acta, Vol. 1062, pp. 142-148, 1991, Elsevier Science Publishers B.V., The Netherlands

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.